Explore how terminal sialylation and fucosylation signatures reflect inflammation, cancer, immune regulation and biotherapeutic quality. This module links glycobiology concepts to LC-MS based released glycan and glycopeptide workflows, and shows how to derive quantitative sialylation and fucosylation metrics suitable for clinical glycan biomarker panels and CQAs.